1033P - Quantitative assessment of inotuzumab ozogamicin (InO) response relative to investigator’s choice of chemotherapy (ICC) in adults with relapsed or refractory (R/R) CD22+ B-Cell acute lymphoblastic leukemia (ALL)
- Resource Type
- Abstract
- Source
- In
Annals of Oncology September 2017 28 Supplement 5:v368-v368 - Subject
- Language
- ISSN
- 0923-7534